Key Event Components

Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
A complete list of all KECs is available in TSV format on the Downloads Page.

Showing 1051 to 1075 of 1141 KECs

ID	Action	Process	Object	Associated Key Events (KEs)


91	decreased	gene expression (GO:0010467)	translocator protein (PR:000016757)	289: Decrease, Translocator protein (TSPO)
90	decreased	gene expression (GO:0010467)	STAR (PR:000015715)	266: Decrease, Steroidogenic acute regulatory protein (STAR)
89	increased	peroxisome proliferator activated receptor signaling pathway (GO:0035357)	peroxisome proliferator-activated receptor alpha (PR:000013056)	227: Activation, PPARα
88	increased	neuron death in response to oxidative stress (GO:0036475)		191: Neuronal dysfunction
87	occurrence	oxidative stress (MP:0003674)		None
86	decreased		glutathione (CHEBI:16856)	None
85	disrupted	protein domain specific binding (GO:0019904)		158: N/A, Interferences with SH-/selen-proteins
84	occurrence	protein binding (GO:0005515)	Selenium-Binding Proteins (MESH:D051137)	261: Binding, SH-/selen-proteins
83	decreased	population growth rate (PCO:0000008)		4 Events 442: Decreased, Population trajectory 361: Decline, Population 679: Decline, Population trajectory 1136: Impaired recruitment , Population trajectory
82	increased	paralysis (MP:0000753)		5 Events 39: Increased Cholinergic Signaling 602: Increased, Ataxia, paralysis, or hyperactivity 764: N/A, Ataxia, paralysis, or hyperactivity 1014: Induction, Somatic muscle paralysis 1019: Induction, pharyngeal muscle paralysis
81	increased	hyperactivity (MP:0001399)		3 Events 39: Increased Cholinergic Signaling 602: Increased, Ataxia, paralysis, or hyperactivity 764: N/A, Ataxia, paralysis, or hyperactivity
80	increased	ataxia (MP:0001393)		3 Events 39: Increased Cholinergic Signaling 602: Increased, Ataxia, paralysis, or hyperactivity 764: N/A, Ataxia, paralysis, or hyperactivity
79	increased	respiratory distress (MP:0001954)		445: Respiratory distress/arrest
78	increased		decreased heart rate (MESH:D001919)	444: Increased, Atrioventricular block and bradycardia
77	increased		atrioventricular block (MESH:D054537)	444: Increased, Atrioventricular block and bradycardia
76	increased		acetylcholine (CHEBI:15355)	10: Acetylcholine accumulation in synapses
75	decreased	acetylcholinesterase activity (GO:0003990)	acetylcholinesterase (PR:000003626)	12: Acetylcholinesterase (AchE) Inhibition
74	functional change	DNA repair (GO:0006281)	deoxyribonucleic acid (CHEBI:16991)	None
73	increased	mutation (MESH:D009154)	deoxyribonucleic acid (CHEBI:16991)	3 Events 185: Increase, Mutations 336: Increase, Heritable mutations in offspring 876: Increase, Mutations in Critical Genes
72	increased	DNA alkylation (GO:0006305)	deoxyribonucleic acid (CHEBI:16991)	97: Alkylation, DNA
71	increased	Disease Susceptibility (MESH:D004198)		323: Increased, Disease susceptibility
70	increased	suppression of host defenses (GO:0044414)	immune system (UBERON:0002405)	403: Suppression, Immune system
69	increased	I-kappaB phosphorylation (GO:0007252)	NF-kappa-B inhibitor (PR:000003292)	145: Induction, IKB inhibitory protein
68	decreased		lymphocyte (CL:0000542)	168: Decreased, Lymphocytes
67	decreased	cytokine production involved in inflammatory response (GO:0002534)		152: Suppression, Inflammatory cytokines